Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Venture Rounds Help Promedior's Lead Program In Multiple Indications

Executive Summary

Roughly a year after raising $15 million in a Series B financing, Promedior announced it had raised another $12 million in a Series C round on March 16, giving the company enough of a financial runway to advance its lead program into multiple indications

You may also be interested in...



FDA Wants Clinically Meaningful Outcomes, Mortality Measured in IPF Trials

Clinical trials for idiopathic pulmonary fibrosis should emphasize efficacy outcomes that are clinically meaningful to patients, and should measure mortality as a means of validating the endpoints chosen, an FDA official said, but exactly what those endpoints are is still uncertain

FDA Wants Clinically Meaningful Outcomes, Mortality Measured in IPF Trials

Clinical trials for idiopathic pulmonary fibrosis should emphasize efficacy outcomes that are clinically meaningful to patients, and should measure mortality as a means of validating the endpoints chosen, an FDA official said, but exactly what those endpoints are is still uncertain

Pirfenidone Panel Highlights Difficulty Of Selecting Primary Endpoint In IPF

Though InterMune's pirfenidone still has the challenge of getting FDA approval based on mixed Phase III data using a not-yet validated primary endpoint, other drugs for idiopathic pulmonary fibrosis may face a clearer path to approvals following the Pulmonary-Allergy Drugs Advisory Committee March 9 review

Topics

Latest News
See All
UsernamePublicRestriction

Register

PS052061

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel